Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2011 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (175)	4/16/2011 2:36:02 AM
From: Ian@SI	1 Recommendation Read Replies (1) \| Respond to of 400

CVR valuation courtesy of Barron's (end of M Santoli's column... One instrument of this description quietly hit the market this month, a "contingent value right" security whose value is tied strictly to the fortunes of one drug developed by Genzyme, the biotech company recently bought by Sanofi-Aventis (SNY). Sanofi paid $74 per share in cash, plus the CVR linked to the progress of Lemtrada, a drug being evaluated for its effect in treating multiple sclerosis. The CVR trades on the Nasdaq under ticker symbol GCVRZ and closed Friday at $2.63. Some hedge-fund investors have been drawn to the CVRs as a "noncorrelated" investment with a definable probability-based estimated value, yet without the cash-burn and operational risks of a typical biotech stock. The CVR's ultimate cash value, between now and its maturity in 2020, is based on production and sales milestones for Lemtrada. The maximum value is $14 per CVR, if every sales threshold is met on time. Of the 10 analysts who have ventured estimates of the likely payout, the average present value of the likely end value is around $3.30, or 25% above the current price. Comparisons with roughly similar "all or nothing" instruments place the present value closer to $4.

To: BulbaMan who wrote (175)	4/21/2011 5:48:46 PM
From: BulbaMan	Read Replies (1) \| Respond to of 400

4/21/11 Contest Update It was a short four-day week but stocks did not come up short. At Thursday’s close, the Nasdaq Biotech Index was up 12.65% YTD (vs. up 12.34% YTD a week ago) and the Contest median was up 10.14% YTD (vs. up 8.49% YTD a week ago). The Nasdaq Composite Index was up 6.31% YTD (vs. up 4.21% YTD a week ago). MCBIO’s portfolio (up 39.12% YTD) picked up a few more percent and held on to the lead, but we have a new second place contender. CRAZYP’s portfolio (up 35.78% YTD) had a huge week, pushing ROCKY’s portfolio (up 33.77% YTD) back to third place. At Thursday's close, 31 of the 38 Contest portfolios were still in the black with 16 of the 38 now beating the NBI. Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks ranked by % Gained and % Lost for the week (foreign stock prices are not converted to US$ in these two tables). Portfolio adjustments: 1) The GENZ CVR (GCVRZ) was added to TECHNET’s portfolio. 2) GNVC 1-10 reverse split became effective. Happy Holidays biotechies! (All corrections, especially adjustments for splits, greatly appreciated.) 4/21/11 Rank Name Profit/Loss 1 MCBIO 39,116 2 CRAZYP 35,775 3 ROCKY 33,771 4 RRGE 33,410 5 IJF 25,527 6 FIB 25,377 7 GENE 18,365 8 RKRW 18,101 9 GEORGIA 17,378 10 IMAN 17,148 Week's Top 5 Gainers Symbol 4/15 4/21 % change AMRN 8.77 16.92 92.97% ACAD 1.77 2.24 26.55% ANTH 5.81 6.86 18.07% ZLCS 2.48 2.89 16.53% GNOM 13.44 15.60 16.07% Week's Top 5 Losers Symbol 4/15 4/21 % change MYG.TO 0.47 0.41 -12.90% NRGX.OB 0.78 0.70 -10.26% RGDX 2.29 2.06 -10.04% VPHM 21.81 19.72 -9.58% ROSG 0.46 0.42 -9.09%